hematological cancer | GenomeWeb

hematological cancer

The firm is developing products suited for pharmaceutical development from biomarker discovery through companion diagnostics and disease monitoring. 

The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.

The company is focusing on hematological malignancies and looking to partner with pharmaceutical companies for companion diagnostics.

Despite an initial focus on cardiovascular disease, Miragen has moved programs in hematological cancer and fibrosis to the front of its pipeline.

The partners will map genomic variation and study its effects on patient outcomes to provide a resource for the prognosis of cancer patients and to help guide treatment for them. 

The deal covers tests based on bone marrow and peripheral blood for hematologic cancers.

One of four new research centers, the collaborative network will look to push genomic and cell therapy technologies into clinical trials. 

The researchers discovered mutations in essentially the same genes and came to very similar conclusions with regard to the increased cancer risk.

NEW YORK (GenomeWeb) – NeoGenomics today reported a 37 percent year-over-year increase in its third quarter revenues.

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Thursday that it has licensed four biomarkers from the University of Tokyo that are believed to play a role in the prognosis of patients with blood cancers.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.